| P2093 | author name string | Andrew S Austin | |
| | Jan G Freeman | |
| | Robert S Lo | |
| P2860 | cites work | Probiotics for patients with hepatic encephalopathy | Q24235259 |
| | Probiotics for hepatic encephalopathy | Q24236083 |
| | Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis | Q24243033 |
| | THE ROMANTIC RATIONALIST: A STUDY OF ELIE METCHNIKOFF | Q24516602 |
| | Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives | Q26864127 |
| | The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis | Q28345942 |
| | Interactions between commensal intestinal bacteria and the immune system | Q29617039 |
| | Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors | Q33408398 |
| | Review of probiotics available to modify gastrointestinal flora. | Q33736490 |
| | Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club | Q33836637 |
| | Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial | Q33872486 |
| | Gut-liver axis | Q33943996 |
| | Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study | Q46680959 |
| | Variceal bleeding in portal hypertension: bacterial infection and comparison of efficacy of intravenous and per-oral application of antibiotics--a randomized trial | Q46691657 |
| | Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study | Q48225158 |
| | II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. | Q50864303 |
| | Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. | Q51059856 |
| | TREATMENT OF HEPATIC ENCEPHALOPATHY BY ALTERATION OF INTESTINAL FLORA WITH LACTOBACILLUS ACIDOPHILUS. | Q51255601 |
| | Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. | Q51368607 |
| | Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. | Q52014877 |
| | Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. | Q52940886 |
| | Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. | Q53536111 |
| | Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers. | Q54180537 |
| | The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. | Q54431259 |
| | Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. | Q54572654 |
| | Lactobacillus acidophilus (Enpac) in Treatment of Hepatic Encephalopathy | Q54655350 |
| | Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. | Q54748967 |
| | Bacterial translocation of enteric organisms in patients with cirrhosis | Q58387749 |
| | Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease | Q61022732 |
| | Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition | Q71581561 |
| | Primary sclerosing cholangitis | Q72596376 |
| | Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites | Q73483441 |
| | Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis | Q73584895 |
| | Histomorphometric study of portal hypertensive enteropathy | Q73911000 |
| | Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites | Q74367030 |
| | Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis | Q77909622 |
| | Probiotics: intestinal gatekeeping, immunomodulation, and hepatic injury | Q81319583 |
| | Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial | Q82112174 |
| | Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial | Q83949904 |
| | Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy | Q84403028 |
| | A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy | Q84953818 |
| | Translocation of Certain Indigenous Bacteria from the Gastrointestinal Tract to the Mesenteric Lymph Nodes and Other Organs in a Gnotobiotic Mouse Model | Q34078678 |
| | Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis | Q34141306 |
| | PROBIOTICS: GROWTH-PROMOTING FACTORS PRODUCED BY MICROORGANISMS. | Q34258740 |
| | How is the liver primed or sensitized for alcoholic liver disease? | Q34272852 |
| | Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis | Q34291661 |
| | Bacterial translocation in cirrhotic rats. Its role in the development of spontaneous bacterial peritonitis | Q34381820 |
| | Infection, coagulation, and variceal bleeding in cirrhosis | Q34400962 |
| | Ethanol, oxidative stress, and cytokine-induced liver cell injury | Q34683423 |
| | Human studies with probiotics and prebiotics: clinical implications | Q34712447 |
| | Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial | Q34750864 |
| | Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. | Q35031260 |
| | Non-alcoholic fatty liver disease: lumen–liver interactions and possible role for probiotics | Q35114267 |
| | Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria | Q35595154 |
| | Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. | Q35595783 |
| | Bacterial DNA activates cell mediated immune response and nitric oxide overproduction in peritoneal macrophages from patients with cirrhosis and ascites. | Q35596596 |
| | Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics | Q35787456 |
| | Colonic microbiome is altered in alcoholism. | Q35994007 |
| | Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis | Q36050135 |
| | Bacterial translocation (BT) in cirrhosis | Q36050434 |
| | The intestinal microbiota in health and disease: the influence of microbial products on immune cell homeostasis | Q36533780 |
| | Review article: alcoholic liver disease--pathophysiological aspects and risk factors. | Q36609894 |
| | Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study | Q37072188 |
| | Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. | Q38308253 |
| | Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study | Q39974377 |
| | Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth | Q41863620 |
| | Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis | Q42653122 |
| | Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy | Q43281074 |
| | Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 |
| | Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: molecular epidemiologic evidence | Q43691333 |
| | Bacterial translocation after cirrhotic liver resection: a clinical investigation of 181 patients | Q43710583 |
| | Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. | Q43954087 |
| | Effect of acute portal hypertension on gut mucosa. | Q44192608 |
| | Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors | Q44333170 |
| | Alteration of intestinal intraepithelial lymphocytes and increased bacterial translocation in a murine model of cirrhosis | Q44651654 |
| | Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial | Q44709594 |
| | Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis | Q44880291 |
| | VSL#3 ® probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis | Q45339638 |
| | Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study | Q46446596 |
| | Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. | Q46533800 |
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| | probiotics | Q1816730 |
| P304 | page(s) | 874768 | |
| P577 | publication date | 2014-01-01 | |
| P1433 | published in | The Scientific World Journal | Q7762585 |
| P1476 | title | Is there a role for probiotics in liver disease? | |
| P478 | volume | 2014 | |